FindTrial
Sign In

Toca FC

DRUG6 trials

Sponsors

Tocagen Inc.

Conditions

Anaplastic AstrocytomaAnaplastic OligoastrocytomaAnaplastic OligodendrogliomaBladder CancerColorectal CancerGlioblastomaGlioblastoma MultiformeHead and Neck Cancer

Phase 1

A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma
CompletedNCT01156584
Tocagen Inc.Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma +1
Start: 2010-07-31End: 2016-08-18Updated: 2018-05-21
Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
CompletedNCT01470794
Tocagen Inc.Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma +1
Start: 2012-02-29End: 2016-04-12Updated: 2018-05-21
Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
CompletedNCT01985256
Tocagen Inc.Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma +1
Start: 2014-02-28End: 2016-03-03Updated: 2018-05-21
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
TerminatedNCT02576665
Tocagen Inc.Bladder Cancer, Colorectal Cancer, Head and Neck Cancer +9
Start: 2016-07-31End: 2019-12-20Updated: 2020-02-07
A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care
WithdrawnNCT02598011
Tocagen Inc.Newly Diagnosed High Grade Glioma (HGG)
Start: 2017-01-31Updated: 2020-03-30

Phase 2

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
TerminatedNCT02414165
Tocagen Inc.Anaplastic Astrocytoma, Glioblastoma Multiforme
Start: 2015-11-30End: 2019-12-20Updated: 2020-02-07

Related Papers

CTNI-42. A BIOMARKER-GUIDED PHASE 2 STUDY OF DB107-RRV (A RETROVIRAL REPLICATING VECTOR) COMBINED WITH DB107-FC (FLUCYTOSINE EXTENDED-RELEASE TABLETS) IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR ANAPLASTIC ASTROCYTOMA: A CLINICAL PROTOCOL
Neuro-Oncology2024-11-01
Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients.
2023-08-1214 citations
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma
JAMA Oncology2020-10-29130 citations
Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma
Clinical Cancer Research2020-08-1827 citations
Immune modulation after Toca 511 and Toca FC treatment of colorectal cancer patients.
Journal of Clinical Oncology2020-02-015 citations
LTBK-08. TOCA 511 & TOCA FC VERSUS STANDARD OF CARE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA
Neuro-Oncology2019-11-0117 citations
Abstract 4771: The addition of toca 511 and 5-FC to temozolomide improves response in a temozolomide-resistant murine glioblastoma model and correlates with toca 511 dose
Experimental and Molecular Therapeutics2019-07-01
Abstract 4771: The addition of toca 511 and 5-FC to temozolomide improves response in a temozolomide-resistant murine glioblastoma model and correlates with toca 511 dose
Cancer Research2019-07-01
Abstract A018: Effects of Toca 511 and Toca FC on tumor microenvironment and peripheral blood populations in patients with advanced malignancies
Cancer Immunology Research2019-02-01
ATIM-26. IMMUNOLOGIC TRENDS ASSOCIATED WITH PATIENT OUTCOMES IN A PHASE 1 CLINICAL TRIAL OF TOCA 511 AND TOCA FC IN RECURRENT HIGH GRADE GLIOMA
Neuro-Oncology2018-11-011 citations
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
2018-09-01131 citations
Abstract CT067: A phase Ib study of Toca 511, a retroviral replicating vector, followed by Toca FC in patients with advanced cancer
Cancer Research2018-07-011 citations
Abstract 5630: Immune profile of tumor microenvironment helps predict response in patients treated with an investigational immunotherapeutic consisting of a retroviral replicating vector (Toca 511) and an extended-release formulation of 5-fluorocytosine (Toca FC)
Cancer Research2018-07-01
25 Durable complete responses observed in patients with recurrent high grade glioma treated with Toca 511 & Toca FC
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques2018-06-011 citations
10 Toca 5: Toca 511 combined with Toca FC versus standard of care in patients undergoing planned resection for recurrent glioblastoma or anaplastic astrocytoma
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques2018-06-011 citations
Toca 6: A phase 1b study of Toca 511 and Toca FC in patients with advanced solid tumors or lymphoma.
Journal of Clinical Oncology2018-05-201 citations
Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer.
2018-05-0812 citations
Toca 511 and Toca FC in patients with gastrointestinal tumors in the Toca 6 study.
Journal of Clinical Oncology2018-02-011 citations
Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment
Molecular Cancer Therapeutics2018-01-01
Abstract B010: Antitumor cellular immune response elicited by Toca 511 and Toca FC therapy in preclinical and clinical studies
Molecular Cancer Therapeutics2018-01-01

45 more papers not shown